Orange Book product · Brand (NDA)

SINUVA

MOMETASONE FUROATE

Brand (NDA)NDA 209310RX INTERSECT ENT INC

Dec 08, 2017

Approved

Brand (NDA)

Application

Not listed

TE code

Listed patents

Approval
FDA approval date of this drug product.
Dec 08, 2017
8 yr 8 mo ago
Patent 9585681 expires
Listed method-of-use patent (U-2272) expiration.
Apr 04, 2026
3 mo ago
Today
Patent 7544192 expires
Listed method-of-use patent (U-2272) expiration.
Nov 29, 2026
in 5 mo
Patent 8025635 expires
Listed drug product patent expiration.
Jun 12, 2027
in 1 yr
Patent 10357640 expires
Listed method-of-use patent (U-2272) expiration.
Oct 03, 2031
in 5 yr 4 mo
Patent 8763222 expires
Listed drug product patent expiration.
Feb 08, 2032
in 5 yr 9 mo
Patent 10406332 expires
Listed drug product patent expiration.
Mar 13, 2034
in 7 yr 10 mo
Patent 10232152 expires
Listed drug product patent expiration.
Nov 24, 2034
in 8 yr 7 mo

Active ingredient

MOMETASONE FUROATE

Strength

1.35MG

Dosage form

IMPLANT

Route

IMPLANTATION

TE code

Not listed

Application

NDA 209310

Product number

001

Marketing status

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
9585681	Apr 04, 2026	3 mo ago	U-2272
7544192	Nov 29, 2026	in 5 mo	U-2272
8025635	Jun 12, 2027	in 1 yr	ProductU-2272
10357640	Oct 03, 2031	in 5 yr 4 mo	U-2272
8763222	Feb 08, 2032	in 5 yr 9 mo	Product
10406332	Mar 13, 2034	in 7 yr 10 mo	Product
10232152	Nov 24, 2034	in 8 yr 7 mo	ProductU-2272